Cargando…
Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study
BACKGROUND: Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear. OBJECTIVES: The aim of this study was to determine whether ear...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436815/ https://www.ncbi.nlm.nih.gov/pubmed/34539162 http://dx.doi.org/10.1097/IPC.0000000000001023 |
_version_ | 1783752054949281792 |
---|---|
author | Paranjape, Neha Husain, Mir Priestley, Jennifer Koonjah, Yashila Watts, Christopher Havlik, Joseph |
author_facet | Paranjape, Neha Husain, Mir Priestley, Jennifer Koonjah, Yashila Watts, Christopher Havlik, Joseph |
author_sort | Paranjape, Neha |
collection | PubMed |
description | BACKGROUND: Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear. OBJECTIVES: The aim of this study was to determine whether early treatment with remdesivir improves clinical outcomes: length of stay, need for mechanical ventilation, and death. METHODS: We conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States. RESULTS: We identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) (P = 0.03). In the ≤3 day group, further reduction in length of stay was seen in those with lower oxygen requirement at baseline (P < 0.0001). Length of stay was lower in the ≤3 day group both with and without the use of corticosteroids (P = 0.0003). The odds of requiring mechanical ventilation were higher for the >3 day group compared with the ≤3 day group (odds ratio, 1.5; 95% confidence interval, 0.8–2.7), and the odds of death were higher for the >3 day group versus the ≤3 day group (odds ratio, 1.74; 95% confidence interval, 0.9–3.2). CONCLUSIONS: Our data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay. |
format | Online Article Text |
id | pubmed-8436815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-84368152021-09-13 Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study Paranjape, Neha Husain, Mir Priestley, Jennifer Koonjah, Yashila Watts, Christopher Havlik, Joseph Infect Dis Clin Pract (Baltim Md) Original Articles BACKGROUND: Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear. OBJECTIVES: The aim of this study was to determine whether early treatment with remdesivir improves clinical outcomes: length of stay, need for mechanical ventilation, and death. METHODS: We conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States. RESULTS: We identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) (P = 0.03). In the ≤3 day group, further reduction in length of stay was seen in those with lower oxygen requirement at baseline (P < 0.0001). Length of stay was lower in the ≤3 day group both with and without the use of corticosteroids (P = 0.0003). The odds of requiring mechanical ventilation were higher for the >3 day group compared with the ≤3 day group (odds ratio, 1.5; 95% confidence interval, 0.8–2.7), and the odds of death were higher for the >3 day group versus the ≤3 day group (odds ratio, 1.74; 95% confidence interval, 0.9–3.2). CONCLUSIONS: Our data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay. Lippincott Williams & Wilkins 2021-09 2021-04-15 /pmc/articles/PMC8436815/ /pubmed/34539162 http://dx.doi.org/10.1097/IPC.0000000000001023 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Original Articles Paranjape, Neha Husain, Mir Priestley, Jennifer Koonjah, Yashila Watts, Christopher Havlik, Joseph Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title | Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title_full | Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title_fullStr | Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title_full_unstemmed | Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title_short | Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study |
title_sort | early use of remdesivir in patients hospitalized with covid-19 improves clinical outcomes: a retrospective observational study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436815/ https://www.ncbi.nlm.nih.gov/pubmed/34539162 http://dx.doi.org/10.1097/IPC.0000000000001023 |
work_keys_str_mv | AT paranjapeneha earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy AT husainmir earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy AT priestleyjennifer earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy AT koonjahyashila earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy AT wattschristopher earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy AT havlikjoseph earlyuseofremdesivirinpatientshospitalizedwithcovid19improvesclinicaloutcomesaretrospectiveobservationalstudy |